Gujarat Magazine

Er+/ Her2 -ve Breast Cancer Market Is Expected to Showcase a Significant Growth During the Forecast Period | Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix

 Breaking News
  • No posts were found

Er+/ Her2 -ve Breast Cancer Market Is Expected to Showcase a Significant Growth During the Forecast Period | Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix

May 30
11:30 2024
Er+/ Her2 -ve Breast Cancer Market Is Expected to Showcase a Significant Growth During the Forecast Period |  Radius Pharmaceuticals, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix
ER+/ HER2 -ve Breast Cancer Market
Upcoming pipeline of ER+, HER2− Breast cancer comprises many next-generation SERD drug candidates. They will face a strong competition from the existing CDK4/6 inhibitors that have a strong hold over majority of the market share. This could lead to their slow growth.

DelveInsight’s “ER+/ HER2 -ve Breast Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the ER+/ HER2 -ve Breast Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The ER+/ HER2 -ve Breast Cancer market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

ER+/ HER2 -ve Breast Cancer Overview

Breast cancer begins when abnormal cancerous cells in the breast start multiplying uncontrollably, forming a tumor. Typically, this process originates in the breast ducts or lobules. These cancer cells receive various growth signals, often in the form of hormones.

Hormone receptors, which are proteins, act as receivers for these signals and instruct cancer cells to proliferate. When breast cancer cells receive signals from estrogen hormones that promote tumor growth, it’s referred to as estrogen receptor-positive (ER+) breast cancer. Similarly, if cancerous cells respond to progesterone hormone signals that stimulate growth, it’s termed progesterone receptor-positive (PR+) breast cancer. Breast cancer falling into either ER+ or PR+ categories is classified as hormone receptor-positive (HR+) breast cancer.

In HER2-negative breast cancer, cells lack significant levels of a protein called HER2 on their surface. These HER2-negative cancer cells tend to grow more slowly and are less prone to recurrence or metastasis compared to those with high HER2 levels. Assessing HER2 status in certain cancer cells can inform treatment strategies.

ER+/ HER2 -ve Breast Cancer Market Key Facts

  • The total incident population of Breast Cancer in the United States is 256,431 in 2021.
  • In the United States, more cases were observed for postmenopausal Breast Cancer, with 205,145 cases in 2021.
  • In 2021, cases of localized, regional, distant and unknown stage were observed to be 164,116, 74,365, 15,386 and 2,564 respectively. This number might increase during forecast period.
  • Among the various subtypes of the disease (localized and regional), ER+/HER2− occupies the maximum patient pool, with 147,977 cases of this category, followed by the number of those with 24,325 cases of Triple-negative and 20,271 cases of ER+/HER2+. On the other hand, HR−/HER2+ accommodated the least number of cases.

ER+/ HER2 -ve Breast Cancer Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted ER+/ HER2 -ve Breast Cancer market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the ER+/ HER2 -ve Breast Cancer market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

ER+/ HER2 -ve Breast Cancer Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

ER+/ HER2 -ve Breast Cancer Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the ER+/ HER2 -ve Breast Cancer market or expected to be launched during the study period. The analysis covers the ER+/ HER2 -ve Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the ER+/ HER2 -ve Breast Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the ER+/ HER2 -ve Breast Cancer Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market

ER+/ HER2 -ve Breast Cancer Market Outlook

Breast cancer ranks as the second most prevalent cancer among both women and men globally. Within the spectrum of breast cancer types, estrogen receptor-positive (ER+) breast cancer stands out as the most frequently diagnosed subtype. ER+ breast cancer cells possess receptors that bind to estrogen, fueling their growth. Approximately two-thirds of breast cancer cases are hormone receptor-positive (HR+), with the majority falling under the ER+ category, as stated by the American Cancer Society.

The stage of breast cancer plays a pivotal role in treatment decisions. Typically, patients with breast cancer in Stages I, II, or III undergo surgery, often followed by radiation therapy. Additionally, most individuals in these stages receive drug therapy, which may include chemotherapy, hormone therapy (such as tamoxifen or aromatase inhibitors), and HER2-targeted drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta). The selection of optimal drugs depends on factors like tumor hormone receptor status, HER2 status, and other clinical considerations.

 

ER+/ HER2 -ve Breast Cancer Therapeutics Analysis

Several major pharma and biotech giants are developing ER+/ HER2-VE Breast Cancer therapies. Currently, AstraZeneca is leading the therapeutics market with its ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage of clinical development. 

The Leading Companies in the ER+/ HER2 -ve Breast Cancer Therapeutics Market Include:

  • AstraZeneca

  • BeiGene

  • CytomX Therapeutics

  • Daiichi Sankyo

  • Eli Lilly

  • EQRx

  • Evgen Pharma

  • G1 Therapeutics

  • Genentech

  • Gilead

  • H3 Biomedicine

  • Jiangsu HengRui Medicine

  • Olema Pharmaceuticals

  • Radius Pharmaceuticals

  • Roche

  • Sanofi

  • Sermonix Pharmaceuticals

  • Tyme

  • Veru

And Many More

ER+/ HER2 -ve Breast Cancer Therapies Covered in the Report Include:

  • BGB-290: BeiGene

  • Camizestrant (AZD9833): AstraZeneca

  • Elacestrant: Radius Pharmaceuticals

  • Giredestrant (RG6171, GDC-9545): Roche

  • Lerociclib (EQ132): EQRx

  • LY3484356 (imlunestrant): Eli Lilly

And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market

Table of Contents

1. Key Insights

2. Executive Summary 

3. ER+/ HER2 -ve Breast Cancer Competitive Intelligence Analysis

4. ER+/ HER2 -ve Breast Cancer Market Overview at a Glance

5. ER+/ HER2 -ve Breast Cancer Disease Background and Overview

6. ER+/ HER2 -ve Breast Cancer Patient Journey

7. ER+/ HER2 -ve Breast Cancer Epidemiology and Patient Population (In the US, EU5, and Japan)

8. ER+/ HER2 -ve Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. ER+/ HER2 -ve Breast Cancer Unmet Needs

10. Key Endpoints of ER+/ HER2 -ve Breast Cancer Treatment

11. ER+/ HER2 -ve Breast Cancer Marketed Products

12. ER+/ HER2 -ve Breast Cancer Emerging Drugs and Latest Therapeutic Advances

13. ER+/ HER2 -ve Breast Cancer Seven Major Market Analysis

14. Attribute Analysis

15. ER+/ HER2 -ve Breast Cancer Market Outlook (In US, EU5, and Japan)

16. ER+/ HER2 -ve Breast Cancer Access and Reimbursement Overview

17. KOL Views on the ER+/ HER2 -ve Breast Cancer Market

18. ER+/ HER2 -ve Breast Cancer Market Drivers

19. ER+/ HER2 -ve Breast Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-market

Other Trending Healthcare Reports By DelveInsight

ER+/ HER2 -ve Breast Cancer Pipeline Insight

“ER+/ HER2-VE Breast Cancer – Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 50+ drugs in ER+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by type, stage, route of administration, and molecule type.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories